News

10x Genomics price target lowered to $12 from $16 at BofA
BofA analyst Michael Ryskin lowered the firm’s price target on 10x Genomics (TXG) to $12 from $16 and keeps a Neutral rating on the shares.
StockStory.org on MSN6d
PacBio (PACB) and Hims & Hers Health (HIMS), 10x Genomics (TXG), Moderna (MRNA) Shares Are Soaring, What You Need To Know
What Happened? A number of stocks jumped in the afternoon session after markets rallied sharply on news that President Trump ...
StockStory.org on MSN6d
Q4 Earnings Outperformers: 10x Genomics (NASDAQ:TXG) And The Rest Of The Life Sciences Tools & Services Stocks
As the Q4 earnings season wraps, let’s dig into this quarter’s best and worst performers in the life sciences tools & ...
10x Genomics price target lowered to $12 from $15 at Barclays
Barclays analyst Luke Sergott lowered the firm’s price target on 10x Genomics (TXG) to $12 from $15 and keeps an Overweight rating on the ...
Forbes6d
10x Genomics
10X Genomics, Inc. is a life science technology company, which engages in building products to interrogate, understand and master biology. Its integrated solutions include single cell ...
U.S. News & World Report4y
10x Genomics Inc - Ordinary Shares - Class A
10X Genomics, Inc. is a life science technology company, which engages in building products to interrogate, understand and master biology. Its integrated solutions include single cell ...
Seeking Alpha26d
10x Genomics: Lower Cost Innovation May Drive A Rebound
Founded in 2012, 10x Genomics (NASDAQ:TXG) is a biotech company developing gene-sequencing solutions based in the US. In a rather competitive market, TXG’s focus has been on single-cell and ...